Macroangiopathy in type II diabetes

1983 ◽  
Vol 104 (4_Suppl) ◽  
pp. S75-S78
Author(s):  
Antti Aro
Keyword(s):  
Coronary Heart Disease ◽  
Heart Disease ◽  
Vascular Disease ◽  
Peripheral Vascular Disease ◽  
Type Ii Diabetes ◽  
Clinical Manifestations ◽  
Diabetic Patients ◽  
Type Ii ◽  
Peripheral Vascular ◽  
Middle Aged

ABSTRACT. Macroangiopathy is the most important cause of mortality and morbidity in type II diabetes. The atherosclerotic process in diabetes is similar to that found in non-diabetic subjects, but the laesions are more extensive and the clinical manifestations are more common in diabetic subjects than in the non-diabetic population. In diabetic patients from different populations, the prevalence of macroangiopathy is variable, and the relative frequency follows the pattern found in the respective non-diabetic populations. The relative risk of large vessel disease is in most populations higher for female than for male diabetics. Coronary heart disease is the most important manifestation of macroangiopathy while cerebrovascular disease and peripheral vascular disease are less frequent, although all these manifestations occur at increased frequency among middle-aged diabetic subjects. The incidence of peripheral vascular disease seems to increase with increasing duration of diabetes in middle-aged subjects, whereas coronary heart disease is particularly frequent in type II diabetes already at the time of the diagnosis. Key words: atherosclerosis, complications, diabetes mellitus, macroangiopathy, mortality.

scholarly journals Pattern of Cardiovascular Diseases in Diabetic population - a seven year study in a tertiary care hospital of Bangladesh

2020 ◽  
Vol 8 (2) ◽  
pp. 96-101
Author(s):  
SM Rezaul Irfan ◽  
Samira Humaira Habib ◽  
Shabnam Jahan Hoque ◽  
AKM Mohibullah
Keyword(s):  
Heart Failure ◽  
Heart Disease ◽  
Cardiovascular Diseases ◽  
Observational Study ◽  
Vascular Disease ◽  
Peripheral Vascular Disease ◽  
Diabetic Patients ◽  
Peripheral Vascular ◽  
Different Types ◽  
Diabetic Population

Background: Cardiac involvement in diabetes covers a wide spectrum, ranging from asymptomatic silent ischemia to clinically evident heart failure. The total number of people with diabetes is projected to rise from 171 million in 2000 to 366 million in 2030. Up to 80% of diabetic patients die of macrovascular complications, including coronary artery disease (CAD), stroke, and peripheral vascular disease (PVD). CVD is the single-most important contributor, and is responsible for 17% of total mortality. Because of the growing numbers of diabetic patients and the increased mortality after their first cardiovascular event, it is critical to identify and treat risk factors early and aggressively in these patients. Methodology: This is a retrospective observational study carried out in the Department of Cardiology BIRDEM General Hospital Dhaka Bangladesh from 2011 to2017. Total 5598 patients who were admitted to the institute between 2011 to 2017 was studied and evaluated to see the pattern of cardiovascular diseases in diabetic population. Results: Among total 5598 patients, 50.02% were male and 49.98% were female. Majority of them were Diabetic and Hypertensive. Most of the patient having cardiovascular disease belongs to age 50-70 years. IHD was found among 1810(32.33%) patients with slightly male predominance. Different types of Cardiomyopathy were found among 330(5.8%) study population. Heart failure of different forms were present among 632 (11.28%) of patients. Different types of Arrhythmia were found among 159 (2.8%) of admitted patient. Rheumatic Vulvular Heart disease were found 64 (1.1%) of individual. Congenital Heart disease were found among 51 with ASD 36 (70.58%) followed by VSD 15 (29.42%) and PAD in 105 (1.8%). Conclusion: This study reflects the higher incidence of Ischemic Heart Disease and higher association of Hypertensive Heart Disease in Diabetic population mostly affecting the 50-70 year age groups. This observational study also shows that the duration of hospital stay has gradually declined over the course of seven years. The incidence of Cardiomyopathy, Peripheral Vascular Disease and Heart Failure could be different in Diabetic population if wide range multicenter prospective approach would have been applied. Bangladesh Crit Care J September 2020; 8(2): 96-101

scholarly journals Peripheral vascular disease risk in diabetic individuals without coronary heart disease

2018 ◽  
Vol 275 ◽  
pp. 419-425 ◽  
Author(s):  
Tanya Wilcox ◽  
Jonathan D. Newman ◽  
Thomas S. Maldonado ◽  
Caron Rockman ◽  
Jeffrey S. Berger
Keyword(s):  
Coronary Heart Disease ◽  
Heart Disease ◽  
Vascular Disease ◽  
Peripheral Vascular Disease ◽  
Disease Risk ◽  
Peripheral Vascular

scholarly journals Lipoprotein(a) and cardiovascular disease: prediction, attributable risk fraction and estimating benefits from novel interventions

2020 ◽  
Author(s):  
Paul Welsh ◽  
Claire Welsh ◽  
Carlos A Celis-Morales ◽  
Rosemary Brown ◽  
Lyn D Ferguson ◽  
...  
Keyword(s):  
Risk Factors ◽  
Coronary Heart Disease ◽  
Heart Disease ◽  
Vascular Disease ◽  
Peripheral Vascular Disease ◽  
Risk Prediction ◽  
Population Attributable Fraction ◽  
Attributable Fraction ◽  
Peripheral Vascular ◽  
Cvd Risk

AbstractBackgroundLipoprotein (a) (Lp(a)) is a CVD risk factor amenable to intervention and might help guide risk prediction.ObjectivesTo investigate the population attributable fraction due to elevated Lp(a) and its utility in risk prediction.MethodsUsing a prospective cohort study, 413,724 participants from UK Biobank, associations of serum Lp(a) with composite fatal/nonfatal CVD (n=10,065 events), fatal CVD (n=3247), coronary heart disease (n=16,649), ischaemic stroke (n=3191), and peripheral vascular disease (n=2716) were compared using Cox models. Predictive utility was determined by C-index changes. The population attributable fraction was estimated.ResultsMedian Lp(a) was 19.7nmol/L (interquartile interval 7.6-75.3nmol/L). 20.8% had Lp(a) values >100nmol/L; 9.2% had values >175nmol/L. After adjustment for classical risk factors, in participants with no baseline CVD and not taking a statin, 1 standard deviation increment in log Lp(a) was associated with a HR for fatal/nonfatal CVD of 1.09 (95%CI 1.07-1.11). Associations were similar for fatal CVD, coronary heart disease, and peripheral vascular disease. Adding Lp(a) to a prediction model containing traditional CVD risk factors improved the C-index by +0.0017 (95% CI 0.0009, 0.0026). We estimated that having Lp(a) values >100nmol/L accounts for 5.7% of CVD events in the whole cohort. We modelled that an ongoing trial to lower Lp(a) in patients with CVD and Lp(a) above ∼175nmol/L may reduce CVD risk by 20.3%, assuming causality, and an achieved Lp(a) reduction of 80%.ConclusionsPopulation screening for elevated Lp(a) may help to predict CVD and target Lp(a) lowering drugs, if such drugs prove efficacious, to those with markedly elevated levels.

scholarly journals Lipoprotein(a) and cardiovascular disease: prediction, attributable risk fraction and estimating benefits from novel interventions

2020 ◽  
Vol 41 (Supplement_2) ◽  
Author(s):  
P Welsh ◽  
C Welsh ◽  
C.A.C Celis-Morales ◽  
R Brown ◽  
L.D Ferguson ◽  
...  
Keyword(s):  
Risk Factors ◽  
Coronary Heart Disease ◽  
Heart Disease ◽  
Vascular Disease ◽  
Peripheral Vascular Disease ◽  
Population Attributable Fraction ◽  
Attributable Fraction ◽  
Funding Source ◽  
Peripheral Vascular ◽  
Cvd Risk

Abstract Background Lipoprotein (a) (Lp(a)) measurement may help guide CVD risk prediction, is thought to be causal in several CVD outcomes, and phase 3 intervention trials of Lp(a) lowering agents are underway. We aimed to investigate the population attributable fraction due to elevated Lp(a) and its utility in CVD risk prediction. Methods In 413,724 participants from UK Biobank, associations of serum Lp(a) with composite fatal/nonfatal CVD (n=10,065 events), fatal CVD (n=3247), coronary heart disease (n=16,649), ischaemic stroke (n=3191), and peripheral vascular disease (n=2716) were compared using Cox models. Predictive utility was determined by C-index changes. The population attributable fraction was estimated. Results Median Lp(a) was 19.7nmol/L (interquartile interval 7.6–75.3nmol/L). 20.8% had Lp(a) values >100nmol/L; 9.2% had values >175nmol/L. After adjustment for classical risk factors, in participants with no baseline CVD and not taking a statin, 1 standard deviation increment in log Lp(a) was associated with a HR for fatal/nonfatal CVD of 1.09 (95% CI 1.07–1.11). Associations were similar for fatal CVD, coronary heart disease, and peripheral vascular disease. Adding Lp(a) to a prediction model containing traditional CVD risk factors improved the C-index by +0.0017 (95% CI 0.0009, 0.0026). We estimated that having Lp(a) values >100nmol/L accounts for 5.7% of CVD events in the whole cohort. We modelled that an ongoing trial to lower Lp(a) in patients with CVD and Lp(a) above ∼175nmol/L may be expected to reduce CVD risk by 20.3%, assuming causality, and an achieved Lp(a) reduction of 80%. Conclusions Population screening for elevated Lp(a) may help to predict CVD and target Lp(a) lowering drugs to those with markedly elevated levels, if such drugs prove efficacious. Population attributable fractions: Lp(a) Funding Acknowledgement Type of funding source: Other. Main funding source(s): Chest, Heart, and Stroke Association Scotland and British Heart Foundation

Tests for Platelet Changes, Acute Phase Reactants and Serum Lipids in Diabetes mellitus and Peripheral Vascular Disease

1982 ◽  
Vol 48 (03) ◽  
pp. 289-293 ◽  
Author(s):  
B A van Oost ◽  
B F E Veldhuyzen ◽  
H C van Houwelingen ◽  
A P M Timmermans ◽  
J J Sixma
Keyword(s):  
Diabetes Mellitus ◽  
Vascular Disease ◽  
Peripheral Vascular Disease ◽  
Acute Phase ◽  
Serum Lipids ◽  
Diabetic Patients ◽  
Peripheral Vascular ◽  
Acute Phase Reactants ◽  
Control Subjects ◽  
And Control

SummaryPlatelets tests, acute phase reactants and serum lipids were measured in patients with diabetes mellitus and patients with peripheral vascular disease. Patients frequently had abnormal platelet tests and significantly increased acute phase reactants and serum lipids, compared to young healthy control subjects. These differences were compared with multidiscriminant analysis. Patients could be separated in part from the control subjects with variables derived from the measurement of acute phase proteins and serum lipids. Platelet test results improved the separation between diabetics and control subjects, but not between patients with peripheral vascular disease and control subjects. Diabetic patients with severe retinopathy frequently had evidence of platelet activation. They also had increased acute phase reactants and serum lipids compared to diabetics with absent or nonproliferative retinopathy. In patients with peripheral vascular disease, only the fibrinogen concentration was related to the degree of vessel damage by arteriography.

Sign in / Sign up

Export Citation Format

Share Document